W. Robert Lee
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
W. Robert Lee is an Assistant Professor in the Department of Radiation Oncology at Duke University in Durham, North Carolina, USA. His research primarily focuses on health outcomes related to prostate cancer, with a particular emphasis on disparities affecting Black men within and outside the Veterans Health Administration. His recent work aims to reconcile these health outcomes and improve patient care.
Articles (11)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2025
Year:
2025
Year:
2025
Year:
2025
385 Background: Trials comparing moderately hypofractionated radiotherapy (MHFRT) against conventionally-fractionated radiotherapy (CFRT) for prostate cancer have varied considerably in intent (non-inferiority vs. superiority) and MHFRT dose. Herein, we compare the efficacy and toxicity profiles of isodose MHFRT and dose-escalated MHFRT. Methods: Individual patient data were obtained from 7 phase III trials comparing MHFRT vs. CFRT: three (n=3454) with isodose and four (n=2426) with dose-escalated MHFRT. Meta-analyses were designed to compare progression-free survival (PFS), late grade ≥2 genitourinary (GU) and late grade ≥2 gastrointestinal (GI) physician-scored toxicity, and clinically-significant decrements in patient-reported urinary or bowel quality of life (QOL). Results: After a median follow-up of 5.4 years (interquartile range [IQR], 4.6-7.2) and 7.1 years (IQR 5.7-8.4) following isodose and dose-escalated MHFRT, there were no differences in PFS (hazard ratio [HR] 0.92, 95%CI 0.81-1.05 and HR 0.94, 95%CI 0.82-1.09, respectively). Neither isodose nor dose-escalated MHFRT were associated with increased odds of grade ≥2 GU toxicity (odds ratio [OR] 1.16 95CI% 0.86-1.57 and OR 1.20, 95%CI 0.95-1.51). The odds of grade ≥2 GI toxicity were higher with dose-escalated (OR 1.48, 95%CI 1.14-1.92) but not isodose MHFRT (OR 1.30, 95% 0.59-2.87). Isodose MHFRT did not show different odds of urinary (OR 1.03, 95%CI 0.51-2.09) and bowel (OR 0.76, 95%CI 0.40-1.43) QOL decrements, while dose-escalated MHFRT was associated with greater odds of bowel (OR 1.68, 95%CI 1.07-2.61), but not urinary (OR 1.57, 95%CI 0.87-2.85), QOL decrement. Conclusions: Isodose MHFRT and dose-escalated MHFRT both have similar efficacy compared with CFRT, but dose-escalated MHFRT is associated with higher physician-scored and patient-reported bowel and urinary toxicity. Isodose regimens, e.g. 60 Gy in 20 fractions, should be the standard MHFRT regimen for localized prostate cancer.
Year:
2025
Patients with nonmetastatic, high‐risk prostate cancer are more likely to die of causes unrelated to their cancer. Identifying patients whose competing risks are a greater threat to their mortality has important implications for treatment decisions.
Year:
2022
Year:
2021
Collaborators (12)
John Nikitas
Assistant Professor
University of Pennsylvania
Quynh Thu Le
Chair and Professor
Stanford University School of Medicine
Donatello Telesca
Professor
University of California Los Angeles Jonathan and Karin Fielding School of Public Health
Emma Hall
Institute of Cancer Research
Sophia Kamran
Massachusetts General Hospital
Wilma Heemsbergen
Researcher
Erasmus University Rotterdam
Paul Corn
Chair
The University of Texas MD Anderson Cancer Center
Susan Halabi
Duke University
Juanita Crook
professor
BC Cancer
James Bates
Associate Professor
Emory University
Luca Incrocci
Full professor
Erasmus University Rotterdam
Deborah W. Bruner
Emory University
Make your next move.
Prepare your application
Review drafts before you send them.